Objective
Bovine Mastitis is a bacterial infection of the cow udder. It is the major problem in the dairy sector, causing losses of approximately €1.5Bn in Europe each year, with each case costing the farmer €285/case. Current treatments use conventional antibiotics. These solutions are not ideal:
- they are not always effective
- bacteria can gain resistance to the antibiotics
- for a period of time during and following treatment (the 'withdrawal period' which can be up to 9.5 days) the milk must be discarded to prevent entry of antibiotic residues into the human food chain
Additionally there is a growing pressure for the need for new antibacterial approaches in animal health to lessen the pressures on existing antibiotics for human usage.
PanaMast is a novel innovative non-antibiotic antimicrobial technology.We are seeking to develop a novel mastitis treatment based on this technology. It is effective against all bacteria tested in the lab, including antibiotic-resistant strains, such as MRSA. Additionally, bacteria have been unable to gain a resistance to PanaMast. PanaMast is composed of natural products, which have a proven safety and toxicity profile. As such, this non-antibiotic approach aims to be the Worlds first Zero-withdrawal product, allowing farmers to sell milk both during and following treatment, while delivering an effective treatment regimen. In preliminary field trials against mastitis caused by Staph. aureus, we have shown a 70% cure rate, compared to a 5-15% cure rate using conventional treatments. This has a range of advantages over current products, namely:
- effective against all bacteria
- ability to treat antibiotic-resistant bacteria
- no resistance to the product
- zero withdrawal period
PanaMast therefore has the potential to dramatically improve the way mastitis is treated, resulting in improved health of cows, lessening of economic losses to the farmer and the dairy sector, and provides a needed solution to the growing antibiotic crisis
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences microbiology bacteriology
- agricultural sciences animal and dairy science dairy
- medical and health sciences basic medicine pharmacology and pharmacy pharmaceutical drugs antibiotics
- medical and health sciences basic medicine pharmacology and pharmacy drug resistance antibiotic resistance
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.2.1.4. - INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Biotechnology
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.2.3.1. - Mainstreaming SME support, especially through a dedicated instrument
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
SME-1 - SME instrument phase 1
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-SMEInst-2014-2015
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
H91 Galway
Ireland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.